Evoke Pharma, Inc.
EVOK
$3.11
-$0.19-5.76%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 9.11% | -3.57% | 19.79% | 20.51% | -17.33% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -20.38% | 26,578.95% | -99.50% | -10.20% | -39.34% |
| Change in Net Operating Assets | -3,315.91% | -102.97% | 132.26% | -399.89% | 1,171.33% |
| Cash from Operations | -51.46% | 0.23% | 68.19% | -133.20% | -6.19% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 16.24% | 913.05% | -96.29% | -- | -- |
| Repurchase of Common Stock | 100.00% | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 200.00% | -- | 100.00% | -257.33% | -- |
| Cash from Financing | 17.37% | 907.74% | -96.08% | 6,422.46% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 4.46% | 511.74% | -110.58% | 505.04% | -17.65% |